List of publications

Prof. Dr. Melanie Hamann

 

Blümel L, Brosda J, Bert B, Hamann M, Dietz GPH (2021).
Moderately aged OFA rats as a novel model for mild age-related alterations in learning and memory.
Brai and Cognition 154:105799, doi: 10.1016/j.bandc.2021.105799.

Nürnberger D, Müller SF, Hamann M, Geyer J (2021). 
First sequencing of caprine Mdr1 (Abcb1) mRNA due to suspected neurological adverse drug reaction in a Thuringian goat following extra-label use of doramectin.
Front Vet Sci 8:682393, doi: 10.3389/fvets.2021.682393.

Ernst L, Zieglowski L, Schulz M, Moss M, Meyer M, Weiskirchen R, Palme R, Hamann M, Talbot SR, Tolba RH (2020).
Severity assessment in mice subjected to carbon tetrachloride.
Sci Rep. 10(1):15790.

 

Hamann M, Niedorf F (2020).
Betrachtung ausgewählter Studien zu Doping und Nachweiszeiten: Wie lassen sich „unabsichtliche“ positive Medikationskontrollen im Pferdesport vermeiden?
DPT 101(10): 982-991.

 

Gäns D, Rummel C, Schmidt M, Hamann M, Geyer J (2019).
Suspected neurological toxicity after oral application of fluralaner (Bravecto®) in a Kooikerhondje dog.
BMC Veterinary Research 15(1):283.

 

Gäns D, Leithäuser C, Hamann M, Geyer J (2019).
Adverse drug reactions after administration of emodepside/praziquantel (Profender®) in an MDR1-mutant Australian Shepherd dog: case report.
Front Vet Sci 6:296.

 

Hamann M (2019).
Die tierärztliche Hausapotheke: Verantwortlichkeiten und Überwachung.
Tierärztliche Umschau 74(9):32-35.

Hamann M (2019).
Fluorchinolone und Cephalosporine der 3./4. Generation: Fragen und Antworten zu den Änderungen der Verordnung über tierärztliche Hausapotheken (TäHaV) für die Kleintiermedizin.
Kleintier.konkret 22(1):32-35.

Hamann M, Plank J, Richter F, Bode C, Smiljanic S, Creed M, Nobrega JN, Richter A (2017).
Alterations of M1 and M4 acetylcholine receptors in the genetically dystonic (dtsz) hamster and moderate antidystonic efficacy of M1 and M4 anticholinergics.
Neuroscience 357: 84-98.

 

Hamann M (2017).
Fluoroquinolones and cephalosporins in small animal medicine - General principles of therapy, selection criteria, diagnostics.
DPT 98: 1020-1036.

 

Hamann M (2017).
Gabapentinoide - die neuen Wundermittel in der Schmerztherapie?
Kleintier.konkret 20: 3-8.

 

Hamann M (2017).
Pharmakotherapie des kardiorenalen Syndroms.
Kleintierpraxis 62 (1): 21-38.

 

Hüske C, Sander SE, Hamann M, Kershaw O, Richter F, Richter A (2016).
Towards optimized anesthesia protocols for stereotactic surgery in rats: Analgesic, stress and general health effects of injectable anesthetics. A comparison of a recommended complete reversal anesthesia with traditional chloral hydrate monoanesthesia.
Brain Res 1642: 364-75. doi: 10.1016/j.brainres.2016.04.019.

 

Richter A, Hamann M, Wissel J, Volk HA (2015).
Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias.
Front Vet Sci 2: 65. doi: 10.3389/fvets.2015.00065. Review.

 

Avchalumov Y, Sander SE, Richter F, Porath K, Hamann M, Bode C, Kirschstein T, Köhling R, Richter A (2014).
Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia.
Exp Neurology 261: 677-684. doi: 10.1016/j.expneurol.2014.08.012.

 

Hamann M (2014).
Überlegungen zum Antibiotika-Einsatz in der Pferdepraxis.
DPT 95 (4): 334-338.

 

Hamann M (2014).
Wichtige arzneimittelrechtliche Fakten für die Pferdepraxis.
Pferde.Spiegel 17 (3): 98-103.

 

Avchalumov Y, Volkmann CE, Rückborn K, Hamann M, Kirschstein T, Richter A, Köhling R (2013).
Persistent changes of corticostriatal plasticity in DTSZ mutant hamsters after age-dependent remission of dystonia.
Neuroscience 250: 60-69.

 

Hamann M (2013).
Update für die Therapie der chronischen Herzinsuffizienz.
Tierärztliches Journal Reise & Medizin, VETfokus Kardiologie 5 (3): 18-20.

 

Hamann M, Sander SE (2013).
Risiken für Anwender und Umwelt durch Tierarzneimittel mit Wirkung auf das Zentralnervensystem.
Kleintierpraxis 58 (1): 21-30.

 

Hamann M, Sander SE (2013).
Gefahr erkannt, Gefahr gebannt.
DPT 94 (5): 462-464.

 

Sander SE, Lemm C, Lange N, Hamann M, Richter A (2012).
Retigabine, a Kv7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Neuropharmacology 62 (2): 1052-1061

 

Kreil A, Hamann M, Sander SE, Richter A (2011).
Changes in dynorphin immunoreactivity but unaltered density of enkephalin immunoreactive neurons in basal ganglia nuclei of genetically dystonic hamsters.
Synapse 65 (11): 1196-1203.

 

Leblois A, Reese R, Labarre D, Hamann M, Richter A, Boraud T, Meissner WG (2010).
Deep brain stimulation changes basal ganglia output firing pattern in the dystonic hamster.
Neurobiol Dis 38 (2): 288-298.

 

Hamann M, Sander SE, Kreil A, Richter A (2010).
Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dtsz mutant hamster.
J Neural Transm 117 (6): 747-757.

 

Lange, N., Hamann, M., Shashidharan, P., Richter, A. (2010).
Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia.
Pharmacol Biochem Behav 97 (4), 647-655.

 

Hamann M, Lange N, Kuschka J, Richter A (2010).
Non-invasive genotyping of transgenic mice: comparison of different commercial kits and required amount.
ALTEX 27 (3): 185-190.

 

Hamann M, Richter A, Fink H, Rex A (2009).
Altered nicotinamide adenine dinucleotide (NADH) fluorescence in dtsz mutant hamsters reflects differences in striatal metabolism between severe and mild dystonia.
J Neurosci Res 87 (3): 776-783.

 

Hamann M, Sander SE, Richter A (2009).
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dtsz mutant hamster.
Eur J Pharmacol 601 (1-3): 99-102.

 

Reese R, Charron G, Nadjar A, Aubert I, Thiolat ML, Hamann M, Richter A, Bezard E, Meissner WG (2009).
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster.
Neurobiol Dis 35 (3): 399-405.

 

Richter F, Hamann M, Richter A (2008).
Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
Brain Res 1188: 148-156.

 

Hamann M, Gernert M, Bennay M, Schwabe K, Koch M, Richter A (2008).
Decreased density of amygdaloid parvalbumin-positive interneurons and behavioral changes in dystonic hamsters (Mesocricetus auratus).
Behav Neurosci 122 (1): 36-43.

 

Hamann M, Sander SE, Richter A (2008).
Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dtsz mutant.
Eur J Pharmacol 586 (1-3): 156-159.

 

Hamann M, Sohr R, Morgenstern R, Richter A (2008).
Extracellular amino acid levels in the striatum of the dtsz mutant, a model of paroxysmal dystonia.
Neuroscience 157 (1): 188-195.

 

Richter F, Hamann M, Richter A (2007).
Chronic rotenone treatment induced behavioral effects, but no pathological signs of parkinsonism in mice.
J Neurosci Res 85 (3): 681-691.

 

Hamann M, Richter A, Meillasson FV, Nitsch C, Ebert U (2007).
Age-related changes in parvalbumin-positive interneurons in the striatum, but not in the sensorimotor cortex in dystonic brains of the dt(sz) mutant hamster.
Brain Res 1150: 190-199.

 

Hamann M, Richter F, Richter A (2007).
Acute effects of neurosteroids in a rodent model of primary paroxysmal dystonia.
Hormones and Behavior 52: 220-227.

 

Sander SE, Hamann M, Richter A (2006).
Age-related changes in striatal NOS-immunoreactive interneurons in the dystonic dtsz mutant hamster.
Neuropath Appl Neurobiol 32 (1): 74-82.

 

Hamann M, Raymond R, Varughesi S, Nobrega JN, Richter A (2006).
Acetylcholine receptor binding and cholinergic interneuron density are unaltered in a genetic animal model of primary paroxysmal dystonia.
Brain Res 1099: 176-182.

 

Hamann M, Sander SE, Richter A (2005).
Age-dependent alterations of striatal calretinin interneuron density in a genetic animal model of primary paroxysmal dystonia.
J Neuropath Exp Neurol, 64 (9): 776-781.

 

Hamann M, Richter A (2004).
Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia.
Neurobiol Dis 16: 78-84.

 

Hamann M, Richter A (2004).
Effects of rubral microinjections of muscimol and bicuculline in a genetic animal model of paroxysmal dystonia.
Brain Res 1008: 126-130.

 

Köhling R, Koch UR, Hamann M, Richter A (2004).
Increased excitability in cortico-striatal synaptic pathway in a model of paroxysmal dystonia.
Neurobiol Dis 16: 236-245.

 

Harnack D, Hamann M, Meissner W, Morgenstern R, Kupsch A, Richter A (2004).
High frequency stimulation of the entopeducular nucleus improves dystonia in dtsz hamsters.
Neuroreport 15: 1391-1393.

 

Richter A, Hamann M (2004).
The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dtsz mutant.
Eur J Pharmacol 502: 105-108.

 

Richter A, Hamann M (2003).
The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
Eur J Pharmacol 478: 47-52.

 

Hamann M, Meisler MH, Richter A (2003).
Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia.
Exp Neurol 184: 830-838.

 

Fedrowitz M, Hamann M, Richter A, Rehders JH, Löscher W, Gernert M (2002).
Effects of locally administered pentylenetetrazole on nigral single unit activity and severity of dystonia in a genetic model of paroxysmal dystonia.
J Neurosci Res 68: 595-603.

 

Hamann M, Richter A (2002).
Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia.
Eur J Pharmacol 443 (1-3): 59-70.

 

Nobrega JN, Raymond R, Barlow K, Hamann M, Richter A (2002).
Changes in AMPA receptor binding in an animal model of inborn paroxysmal dystonia.
Exp Neurol 176: 371-376.

Richter A, Hamann M (2001).
Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary dystonia.
Br J Pharmacol 134: 343-352.

 

Gernert M, Hamann M, Bennay M, Löscher W, Richter A (2000).
Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia.
J Neurosci 20: 7052-7058.

 

Richter A, Hamann M, Bartling C (2000).
CGS 21680 exerts marked antidystonic effects in a genetic rodent model of paroxysmal dyskinesia.
Eur J Pharmacol 404: 299-302.